Cardiol Therapeutics Files $150M Base Shelf Prospectus, Enabling Future Offerings Of Shares, Debt, Warrants And Other Securities
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today
Cardiol filed paperwork that lets them raise up to $150 million by selling new stock or other investments whenever they want. This gives them money for their work, but it also means more shares could be created soon.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.